Close

GlaxoSmithKline (GSK) Announces Positive Data from 7-Year Benlysta Study in SLE Patients

November 16, 2016 11:06 AM EST Send to a Friend
GlaxoSmithKline (NYSE: GSK) announced results from a 7-year safety and efficacy continuation study for Benlysta® (belimumab) in patients with active ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login